Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Breast Cancer Res Treat
Päätekijät: Metzger-Filho, Otto, de Azambuja, Evandro, Procter, Marion, Krieguer, Magalie, Smith, Ian, Baselga, Jose, Cameron, David, Untch, Michael, Jackisch, Christian, Bell, Richard, Gianni, Luca, Goldhirsch, Aron, Piccart, Martine, Gelber, Richard D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947530/
https://ncbi.nlm.nih.gov/pubmed/26708471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3656-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia